Symbol="GTBP"
AssetType="Common Stock"
Name="GT Biopharma Inc"
Description="GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California."
CIK="109657"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="1825 K STREET, SUITE 510, WASHINGTON, D.C., DC, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="10541700"
EBITDA="-6760000"
PERatio="None"
PEGRatio="None"
BookValue="0.354"
DividendPerShare="0"
DividendYield="0"
EPS="-0.47"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.512"
ReturnOnEquityTTM="-1.016"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.47"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="3.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="2.857"
EVToRevenue="-"
EVToEBITDA="-0.751"
Beta="0.955"
num_52WeekHigh="3"
num_52WeekLow="0.18"
num_50DayMovingAverage="0.303"
num_200DayMovingAverage="0.88"
SharesOutstanding="37434900"
DividendDate="2017-08-21"
ExDividendDate="None"
symbol="GTBP"
open="0.28"
high="0.30"
low="0.28"
price="0.28"
volume="368221.00"
latest_trading_day="2023-07-21"
previous_close="0.28"
change="-0.00"
change_percent="-0.5650%"
aroon_positive_momentum_days="9"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="9"
Volume_recent_avg="409253"
Change_recent_avg="-0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-2.92"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="9"
Aroon_momentum_negative="91"
image_negative_thumbnail_id_1="129"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0047.jpeg"
image_negative_thumbnail_id_2="1091"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0124.jpeg"
image_neutral_thumbnail_id_1="580"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0019.jpeg"
image_neutral_thumbnail_id_2="432"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Neutral_Landscape_0019.jpeg"
image_positive_thumbnail_id_1="677"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0031.jpeg"
image_positive_thumbnail_id_2="704"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0004.jpeg"
image_professor_thumbnail_id_1="1184"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
image_professor_thumbnail_id_2="1196"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
